目的 探討尼莫地平聯(lián)合曲伏前列素滴眼液治療原發(fā)性開角型青光眼的臨床效果。方法 選取2015年12月—2017年12月洛陽博愛眼科醫(yī)院收治的原發(fā)性開角型青光眼患者80例，隨機(jī)分成對(duì)照組（40例）和治療組（40例）。對(duì)照組患者睡前滴入曲伏前列素滴眼液，1滴/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服尼莫地平片，1片/次，3次/d。兩組均連續(xù)治療12周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者24 h峰值眼壓、視功能相關(guān)的生存質(zhì)量量表-25（NEI VFQ-25）總分、視盤參數(shù)和視野平均缺損（MD）及視盤篩板血流參數(shù)。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為75.0%和92.5%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組24 h峰值眼壓顯著下降（P<0.05），NEI VFQ-25總分顯著升高（P<0.05），且治療組24 h峰值眼壓和NEI VFQ-25總分明顯好于對(duì)照組（P<0.05）。治療后，兩組垂直杯盤比（C/D）、平均C/D和視野MD值均顯著降低（P<0.05），盤沿面積（RA）值顯著升高（P<0.05），且治療組視盤參數(shù)和視野MD明顯好于對(duì)照組（P<0.05）。治療后，兩組各視盤篩板血流速度、血流量和紅細(xì)胞移動(dòng)速率值均明顯升高（P<0.05），且治療組視盤篩板血流參數(shù)明顯高于對(duì)照組（P<0.05）。結(jié)論 尼莫地平聯(lián)合曲伏前列素滴眼液治療原發(fā)性開角型青光眼能明顯控制患者眼壓，改善篩板區(qū)血流狀態(tài)，延緩病情進(jìn)展，提高生活質(zhì)量。

Objective To investigate the clinical effect of nimodipine combined with travoprost in treatment of primary open-angle glaucoma. Methods Patients (80 cases) with primary open-angle glaucoma in Luoyang Boai Ophthalmological Hospital from December 2015 to December 2017 were randomly divided into control (40 cases) and treatment (40 cases) groups. Patients in the control group were dropped administered with Travoprost Eye Drops at bedtime, 1 drop/time, once daily. Patients in the treatment group were po administered with Nimodipine Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the 24 h peak IOP, NEI VFQ-25 scores, optic disc parameters, visual field MD, blood flow parameters of disc cribriform plates in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 75.0% and 92.5% respectively, and there were differences between two groups (P<0.05). After treatment, the 24 h peak IOP in two groups was significantly decreased (P<0.05), but NEI VFQ-25 scores were significantly increased (P<0.05), and the 24 h peak IOP and NEI VFQ-25 scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the vertical C/D, average C/D and vision MD value in two groups was significantly decreased (P<0.05), but RA value was significantly increased (P<0.05), and the optic disc parameters, the visual field MD in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the blood flow rate, blood flow and erythrocyte migration rate of disc cribriform plates in two groups were significantly increased (P<0.05), and the blood flow parameters of disc cribriform plates in the treatment group were significantly higher than that in the control group (P<0.05). Conclusion Nimodipine combined with travoprost in treatment of primary open-angle glaucoma can obviously control the intraocular pressure of patients, improve the blood flow state in the cribriform plate area, delay the progress of the disease, and improve the quality of life.